What to look forward to in GaBI Journal, 2015, Issue 2
Pro-generics policies and the backlog in medicines registration in South Africa: implications for access to essential and affordable medicines
Product naming, pricing, and market uptake of biosimilars
Differences in pharmacokinetic behaviour of branded enoxaparin and a US generic version in a non-human primate model
Pharmaceutical pricing in Croatia: a comparison of ordinances in 2013 versus 2009 and their potential savings to provide future guidance
Norway, biosimilars in different funding systems. What works?
Korean regulations for biosimilars
Update on US state legislation on biosimilars substitution
Sourcing innovator products in the age of biosimilar research
Online biosimilars resource for patients across Latin America
Source URL: http://gabi-journal.net/20152-gabi-journal-table-of-contents.html
Copyright ©2022 GaBI Journal unless otherwise noted.